Results 251 to 260 of about 231,111 (314)

ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. [PDF]

World J Surg Oncol
Gao Q, You YN, Lian S, Pan C, Zhang ZL, Li KS.   +5 more
europepmc   +1 more source

Deep Learning-Derived Pathomic Features Predict NCIT Efficacy in Resectable Locally Advanced ESCC: Clinical Utility and Mechanistic Insights. [PDF]

Curr Oncol
Zhu K, Tong J, Duan Y, Li Y, Feng Y, Han Y, Xiao X, Han Z, Xia S.   +8 more
europepmc   +1 more source

[Specific active immunotherapy of cancer].

Anales de la Real Academia Nacional de Medicina, 1982
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Active Immunotherapy of Cancer

Immunological Investigations, 2015
Clinical progress in the field of cancer immunotherapy has been slow for many years but within the last 5 years, breakthrough successes have brought immunotherapy to the forefront in cancer therapy. Promising results have been observed in a variety of cancers including solid tumors and hematological malignancies with adoptive cell therapy using natural
Thinle, Chodon, Richard C, Koya, Kunle, Odunsi   +2 more
openaire   +2 more sources

Venom immunotherapy induces monocyte activation

Clinical & Experimental Allergy, 2001
Background Venom immunotherapy (VIT) is an efficient treatment of hymenoptera venom allergy. The mechanism of VIT is based on the induction of tolerance of allergen‐specific Th2 cells. The mechanisms of this T cell modulation are unknown, and could depend on cytokines produced by other cell types such as interleukin (IL)‐12, tumour necrosis factor (TNF)
A, Magnan, V, Marin, L, Mély, J, Birnbaum, S, Romanet, P, Bongrand, D, Vervloet   +6 more
openaire   +2 more sources

Active immunotherapy in colorectal cancer

Seminars in Surgical Oncology, 1989
AbstractSeventy‐four patients with Dukes' B2 through C3 colon or rectal cancer were entered into a prospectively randomized, controlled trial of active specific immunotherapy (ASI) with an autologous tumor cell‐BCG vaccine. Primary tumors were dissociated enzymatically and cryopreserved by techniques that maintain cell viability.
H C, Hoover, M G, Hanna
openaire   +2 more sources

Active Specific Immunotherapy Against Adenocarcinomas

Cancer Investigation, 1994
(1994). Active Specific Immunotherapy Against Adenocarcinomas. Cancer Investigation: Vol. 12, No. 1, pp. 46-56.
G D, MacLean, M A, Reddish, M B, Bowen-Yacyshyn, S, Poppema, B M, Longenecker   +4 more
openaire   +2 more sources

Active immunotherapy of multiple myeloma

European Journal of Cancer, 2006
Since myeloma cells express various potential target antigens, active immunotherapy is being investigated as a novel treatment modality for myeloma. Immunization against the clonal myeloma immunoglobulin (idiotype) elicits protective immunity in mouse models.
Houet, Leonora, Veelken, Hendrik
openaire   +3 more sources